Key Points

  • Secondary ITP complicates the clinical course of chronic LPDs in up to 5% of patients and is poorly responsive to conventional treatments.

  • Eltrombopag is effective in increasing platelet count to safe levels in most patients, thus postponing otherwise unnecessary chemotherapy.

Abstract

Immune thrombocytopenia (ITP) secondary to chronic lymphoproliferative disorders (LPDs) is poorly responsive to conventional treatments. We conducted a multicenter phase 2 prospective 24-week study in 18 patients with ITP secondary to LPDs to assess the safety and efficacy of eltrombopag. Responsive patients entered an extension study for up to 5 years. For inclusion, patients should not require cytotoxic treatment and should have a platelet count <30 × 109/L or have symptoms of bleeding. Eltrombopag was initiated at 50 mg/day, with a maximum of 150 mg/day. The primary end point was platelet response after 4 weeks. Median age was 70 years (range, 43-83 years), and 14 patients had chronic lymphocytic leukemia, 2 had classic Hodgkin lymphoma, and 2 had Waldenström macroglobulinemia. All patients had received previous ITP treatments. Response rate at week 4 was 78% (95% confidence interval [CI], 58%-97%), with 50% of patients having a complete response (CR) (95% CI, 43%-57%); respective results at week 24 were 59% (95% CI, 36%-82%) with 30% reaching a CR (95% CI, 8%-52%). Median exposure to eltrombopag was 16 months; median dose at week 4 was 50 mg/day (range, 25-100 mg/day), and at week 24, it was 50 mg/day (range, 25-150 mg/day). No grade >2 adverse events were reported. Eltrombopag is active and well tolerated in ITP secondary to LPDs. This trial was registered at www.clinicaltrials.gov as #NCT01610180.

REFERENCES

REFERENCES
1.
Lambert
MP
,
Gernsheimer
TB
.
Clinical updates in adult immune thrombocytopenia
.
Blood
.
2017
;
129
(
21
):
2829
-
2835
.
2.
Rodeghiero
F
,
Ruggeri
M
.
Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists
.
Semin Hematol
.
2015
;
52
(
1
):
16
-
24
.
3.
Bussel
JB
,
Cheng
G
,
Saleh
MN
, et al
.
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
.
N Engl J Med
.
2007
;
357
(
22
):
2237
-
2247
.
4.
Visco
C
,
Rodeghiero
F
.
Immune thrombocytopenia in lymphoproliferative disorders
.
Hematol Oncol Clin North Am
.
2009
;
23
(
6
):
1261
-
1274
.
5.
Cines
DB
,
Bussel
JB
,
Liebman
HA
,
Luning Prak
ET
.
The ITP syndrome: pathogenic and clinical diversity
.
Blood
.
2009
;
113
(
26
):
6511
-
6521
.
6.
Visco
C
,
Ruggeri
M
,
Laura Evangelista
M
, et al
.
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia
.
Blood
.
2008
;
111
(
3
):
1110
-
1116
.
7.
Moreno
C
,
Hodgson
K
,
Ferrer
G
, et al
.
Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance
.
Blood
.
2010
;
116
(
23
):
4771
-
4776
.
8.
Zufferey
A
,
Kapur
R
,
Semple
JW
.
Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)
.
J Clin Med
.
2017
;
6
(
2
):
9.
Caligaris-Cappio
F
,
Ghia
P
.
Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?
J Clin Oncol
.
2008
;
26
(
27
):
4497
-
4503
.
10.
Visco
C
,
Barcellini
W
,
Maura
F
,
Neri
A
,
Cortelezzi
A
,
Rodeghiero
F
.
Autoimmune cytopenias in chronic lymphocytic leukemia
.
Am J Hematol
.
2014
;
89
(
11
):
1055
-
1062
.
11.
Hamblin
TJ
.
Autoimmune complications of chronic lymphocytic leukemia
.
Semin Oncol
.
2006
;
33
(
2
):
230
-
239
.
12.
Swerdlow
SH
,
Campo
E
,
Harris
NL
, et al
.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
. 4th ed.
Lyon, France
:
IARC
;
2008
.
13.
Simon
R
.
Optimal two-stage designs for phase II clinical trials
.
Control Clin Trials
.
1989
;
10
(
1
):
1
-
10
.
14.
Koehrer
S
,
Keating
MJ
,
Wierda
WG
.
Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP
.
Leukemia
.
2010
;
24
(
5
):
1096
-
1098
.
15.
European Medicines Agency
. Revolade (eltrombopag). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/revolade#product-information-section. Accessed 2 May 2019.
16.
Paul
S
,
Jain
N
,
Ferrajoli
A
, et al
.
A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia
.
Br J Haematol
.
2019
;
185
(
3
):
606
-
608
.
17.
D’Arena
G
,
Cascavilla
N
.
Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia
.
Leuk Lymphoma
.
2011
;
52
(
4
):
701
-
704
.
18.
Gudbrandsdottir
S
,
Frederiksen
H
,
Hasselbalch
H
.
Thrombopoietin-receptor agonists in haematological disorders: the Danish experience
.
Platelets
.
2012
;
23
(
6
):
423
-
429
.
19.
Sinisalo
M
,
Sankelo
M
,
Itälä-Remes
M
.
Thrombopoietin receptor agonists can be used temporarily with patients suffering from refractory chronic lymphocytic leukemia-associated immunologic thrombocytopenia
.
Leuk Lymphoma
.
2011
;
52
(
4
):
724
-
725
.
20.
Tadmor
T
,
Polliack
A
.
Expanding the use of thrombopoietin mimetic drugs: what about chronic lymphocytic leukemia?
Leuk Lymphoma
.
2011
;
52
(
4
):
558
-
559
.
21.
Rodeghiero
F
,
Carli
G
.
Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists
.
Ann Hematol
.
2017
;
96
(
9
):
1421
-
1434
.
22.
Durot
E
,
Tomowiak
C
,
Michallet
AS
, et al
.
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)
.
Br J Haematol
.
2017
;
179
(
3
):
439
-
448
.
23.
Rodeghiero
F
,
Stasi
R
,
Gernsheimer
T
, et al
.
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
.
Blood
.
2009
;
113
(
11
):
2386
-
2393
.
24.
Rodeghiero
F
.
Is ITP a thrombophilic disorder?
Am J Hematol
.
2016
;
91
(
1
):
39
-
45
.
You do not currently have access to this content.